|
Achilles Therapeutics PLC (ACHL) DCF تقييم
GB | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Achilles Therapeutics plc (ACHL) Bundle
تبسيط تقييم Achilles Therapeutics PLC (ACHL) مع هذه الآلة الحاسبة DCF القابلة للتخصيص! يضم بيانات AChilles Therapeutics PLC (ACHL) الحقيقية ومدخلات التنبؤ القابلة للتعديل ، يمكنك اختبار السيناريوهات وكشف القيمة العادلة ACHilles Therapeutics PLC (ACHL) في دقائق.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -13.5 | -33.0 | -57.8 | -78.4 | -70.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .3 | .8 | 3.3 | 3.7 | 4.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -13.8 | -33.7 | -61.1 | -82.1 | -75.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 97.6 | 177.8 | 266.3 | 173.3 | 131.5 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.5 | 7.3 | 11.2 | 16.0 | 10.4 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .5 | 1.8 | 5.1 | 4.6 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .9 | 6.3 | 3.7 | 5.2 | 5.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.9 | -11.8 | -7.6 | -7.5 | -1.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -0.7098 | -0.7098 | -0.7098 | -0.7098 | -0.7098 | -0.7098 | -0.7098 | -0.7098 | -0.7098 | -0.7098 |
| EBITAT | -13.8 | -33.7 | -61.1 | -82.2 | -75.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -18.5 | -43.5 | -75.2 | -88.9 | -61.4 | 4.7 | .0 | .0 | .0 | .0 |
| WACC, % | 9.77 | 9.77 | 9.77 | 9.77 | 9.77 | 9.77 | 9.77 | 9.77 | 9.77 | 9.77 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 4.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 4 | |||||||||
| Net Debt | -127 | |||||||||
| Equity Value | 131 | |||||||||
| Diluted Shares Outstanding, MM | 40 | |||||||||
| Equity Value Per Share | 3.28 |
What You Will Get
- Real ACHL Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess Achilles Therapeutics' future performance.
- User-Friendly Design: Designed for professionals while remaining easy to use for newcomers.
Key Features
- 🔍 Real-Life ACHL Financials: Pre-filled historical and projected data for Achilles Therapeutics plc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Achilles’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Achilles’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Gain immediate access to the Excel-based ACHL DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates the intrinsic value of Achilles Therapeutics plc (ACHL).
- Test Scenarios: Experiment with different assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial strategy.
Why Choose This Calculator for Achilles Therapeutics plc (ACHL)?
- All-in-One Solution: Integrates DCF, WACC, and financial ratio analyses tailored for Achilles Therapeutics.
- Flexible Inputs: Modify the yellow-highlighted fields to explore different financial scenarios.
- In-Depth Analysis: Automatically computes the intrinsic value and Net Present Value for ACHL.
- Preloaded Information: Access to historical and projected data for reliable starting points.
- High-Quality Standards: Perfect for financial analysts, investors, and consultants focused on the biotech sector.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Achilles Therapeutics plc (ACHL) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Achilles Therapeutics plc (ACHL).
- Consultants: Deliver professional valuation insights regarding Achilles Therapeutics plc (ACHL) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Achilles Therapeutics plc (ACHL) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Achilles Therapeutics plc (ACHL).
What the Template Contains
- Historical Data: Includes Achilles Therapeutics' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Achilles Therapeutics' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Achilles Therapeutics' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.